Tony Elliott

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 1.9K citations · Full text

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini et al. · The Lancet Oncology · 2019 · 632 citations · Full text

Genomics of lethal prostate cancer at diagnosis and castration resistance

Joaquı́n Mateo, George Seed, Cláudia Bertan et al. · Journal of Clinical Investigation · 2019 · 292 citations · Full text

Urology, Oncology, Genomic Aberrations +13

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Ian F. Tannock, Karim Fizazi, Camilla Thellenberg Karlsson et al. · The Lancet Oncology · 2013 · 285 citations

Aflibercept Versus Placebo, Urology, Oncology +7